Page last updated: 2024-11-10

l 683590

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

immunomycin: from Streptomyces hygroscopicus; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5282071
CHEMBL ID8597
CHEBI ID29582
CHEBI ID94818
SCHEMBL ID25512
MeSH IDM0211926

Synonyms (65)

Synonym
nsc 106410
c43h69no12
BRD-K88998544-001-02-4
fr-900520
IDI1_033788
BSPBIO_001318
fr 900520
15,19-epoxy-3h-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,7,20,21(4h,23h)-tetrone, 8-ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-(2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl)-14,16-dimethoxy-4,10,12,18-tetram
fk 520
l 683590
15,19-epoxy-3h-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,7,20,21(4h,23h)-tetrone, 5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-8-ethyl-3-(2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl)-14,16-dimethoxy-4,10,12,18-tetramethy
fr 520
nsc-106410
immunomycin
fk520
ascomycin from streptomyces hygroscopicus var. ascomyceticus
NCGC00163418-02
NCGC00163418-01
fk-520
changchuanmycin
HMS1989B20
chebi:29582 ,
CHEMBL8597 ,
l-683590
HMS1361B20
HMS1791B20
(e)-17-ethyl-1,14-dihydroxy-12-[(e)-2-(4-hydroxy-3-methoxy-cyclohexyl)-1-methyl-vinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo[22.3.1.0*4,9*]octacos-18-ene-2,3,10,16-tetraone
17-ethyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxy-cyclohexyl)-1-methyl-vinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo[22.3.1.0*4,9*]octacos-18-ene-2,3,10,16-tetraone
(e)-(9s,12s,13r,14s,17r,21s,23s,24r,25s,27s)-17-ethyl-1,14-dihydroxy-12-[(e)-2-((1r,3r,4r)-4-hydroxy-3-methoxy-cyclohexyl)-1-methyl-vinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo[22.3.1.0*4,9*]octacos-18-ene-2,3,10,16-tetraone
(ascomycin)17-ethyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxy-cyclohexyl)-1-methyl-vinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo[22.3.1.0*4,9*]octacos-18-ene-2,3,10,16-tetraone
(e)-(s)-17-ethyl-1,14-dihydroxy-12-[(e)-2-(4-hydroxy-3-methoxy-cyclohexyl)-1-methyl-vinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo[22.3.1.0*4,9*]oct acos-18-ene-2,3,10,16-tetraone
bdbm50068939
AKOS015916691
unii-auf4u5nsjk
l-683,590
l 683,590
auf4u5nsjk ,
S7411
BRD-K99369265-001-01-4
HY-13557
CS-1516
SCHEMBL25512
(3s,4r,5s,8r,9e,12s,14s,15r,16s,18r,19r,26as)-8-ethyl-5,19-dihydroxy-3-{(1e)-1-[(1r,3r,4r)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3h-15,19-epoxypyrid
ZDQSOHOQTUFQEM-NURRSENYSA-N
ascomycin (fk520)
(3s,4r,5s,8r,9e,12s,14s,15r,16s,18r,19r,26as)-8-ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[(1e)-2-[(1r,3r,4r)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-3h-py
ascomycin(fk 520)
HB0123
(3s,4r,5s,8r,9e,12s,14s,15r,16s,18r ,19r,26as)-8-ethyl-5,6,8,11,12,13,14,15,16,17,18,1 9,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[(1e )-2-[(1r,3r,4r)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetrameth yl-15,19-epoxy-3
HMS3402B20
135635-46-0
tacrolimus monohydrate impurity a [ep impurity]
tacrolimus impurity, ascomycin- [usp impurity]
fr-520
mfcd06198665
(1r,9s,12s,13r,14s,17r,18e,21s,23s,24r,25s,27r)-17-ethyl-1,14-dihydroxy-12-[(1e)-1-[(1r,3r,4r)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0?,?]octacos-18-ene-2,3,10,16-tetrone
CHEBI:94818
(1r,9s,12s,13r,14s,17r,18e,21s,23s,24r,25s,27r)-17-ethyl-1,14-dihydroxy-12-[(1e)-1-[(1r,3r,4r)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetrone
DTXSID80894126
Q4803998
ascomycin (fk 520, fr 900520, imm
CCG-270483
EX-A1796
(1r,9s,12s,13r,14s,17r,18e,21s,23s,24r,25s,27r)-17-ethyl-1,14-dihydroxy-12-[(e)-1-[(1r,3r,4r)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone
(3s,4r,5s,8r,9e,12s,14s,15r,16s,18r,19r,22r,26as)-8-ethyl-5,19-dihydroxy-3-{(1e)-1-[(1r,3r,4r)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3h-15,19-epoxyp

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Besides, for reducing the consumption of rabbits and the variation of the data, we designed a consecutive sampling method in pharmacokinetic study, with only seven rabbits consumed for each formulation."( Pharmacokinetic study of sirolimus ophthalmic formulations by consecutive sampling and liquid chromatography-tandem mass spectrometry.
Shi, M; Tang, Z; Wang, L; Wang, Q, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" dosing in monkeys using an ex vivo whole blood IL-2 production assay."( Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases.
BaMaung, NY; Clark, RF; Fey, TA; Gauvin, DM; Gunawardana, IW; Henry, CL; Kawai, M; Kopecka, H; Krause, R; Lane, BC; Liu, L; Luly, JR; Marsh, K; Miller, L; Mollison, KW; Or, YS; Pong, M; Rhoades, TA; Sheets, MP; Smith, ML; Trevillyan, JM; Tu, NP; Wagner, R; Wiedeman, PE; Xie, Q, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
immunosuppressive agentAn agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response.
antifungal agentAn antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce.
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
macrolideA macrocyclic lactone with a ring of twelve or more members derived from a polyketide.
etherAn organooxygen compound with formula ROR, where R is not hydrogen.
lactolCyclic hemiacetals formed by intramolecular addition of a hydroxy group to an aldehydic or ketonic carbonyl group. They are thus 1-oxacycloalkan-2-ols or unsaturated analogues.
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency15.84890.003245.467312,589.2998AID2517
regulator of G-protein signaling 4Homo sapiens (human)Potency0.47440.531815.435837.6858AID504845
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency3.98110.035520.977089.1251AID504332
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.03980.010039.53711,122.0200AID1479
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency6.30960.00798.23321,122.0200AID2546
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Peptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)IC50 (µMol)0.00210.00040.39373.6000AID69106; AID69107
Peptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)IC50 (µMol)8.00000.01605.12878.0000AID223386
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Peptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)EC50 (µMol)0.00160.00090.44812.2000AID69103; AID69120
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (32)

Processvia Protein(s)Taxonomy
protein peptidyl-prolyl isomerizationPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
heart morphogenesisPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
protein foldingPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
'de novo' protein foldingPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
regulation of skeletal muscle contraction by regulation of release of sequestered calcium ionPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
protein maturation by protein foldingPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
positive regulation of protein bindingPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
regulation of protein localizationPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
negative regulation of activin receptor signaling pathwayPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
protein refoldingPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
T cell activationPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
regulation of immune responsePeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
ventricular cardiac muscle tissue morphogenesisPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
regulation of ryanodine-sensitive calcium-release channel activityPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
heart trabecula formationPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
calcium ion transmembrane transportPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
supramolecular fiber organizationPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
regulation of amyloid precursor protein catabolic processPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
amyloid fibril formationPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
protein foldingPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
steroid hormone receptor complex assemblyPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
copper ion transportPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
embryo implantationPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
negative regulation of neuron projection developmentPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
androgen receptor signaling pathwayPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
prostate gland developmentPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
negative regulation of microtubule polymerization or depolymerizationPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
negative regulation of microtubule polymerizationPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
protein-containing complex localizationPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
male sex differentiationPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
chaperone-mediated protein foldingPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
protein peptidyl-prolyl isomerizationPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (20)

Processvia Protein(s)Taxonomy
peptidyl-prolyl cis-trans isomerase activityPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
transforming growth factor beta receptor bindingPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
protein bindingPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
macrolide bindingPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
FK506 bindingPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
channel regulator activityPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
signaling receptor inhibitor activityPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
type I transforming growth factor beta receptor bindingPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
transmembrane transporter bindingPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
I-SMAD bindingPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
activin receptor bindingPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
RNA bindingPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
peptidyl-prolyl cis-trans isomerase activityPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
protein bindingPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
ATP bindingPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
GTP bindingPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
FK506 bindingPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
protein-macromolecule adaptor activityPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
heat shock protein bindingPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
copper-dependent protein bindingPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
nuclear glucocorticoid receptor bindingPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
tau protein bindingPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
phosphoprotein bindingPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
cytoplasmPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
cytosolPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
terminal cisternaPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
membranePeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
sarcoplasmic reticulumPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
Z discPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
cytoplasmic side of membranePeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
ryanodine receptor complexPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
sarcoplasmic reticulum membranePeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
cytoplasmPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
nucleoplasmPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
mitochondrionPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
cytosolPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
microtubulePeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
neuronal cell bodyPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
axonal growth conePeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
perinuclear region of cytoplasmPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
extracellular exosomePeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
protein-containing complexPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
cytoplasmPeptidyl-prolyl cis-trans isomerase FKBP4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID22338650% inhibitory concentration of competitive binding against hCyp-18 PPIase activity using uncoupled assay2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Design of a Gag pentapeptide analogue that binds human cyclophilin A more efficiently than the entire capsid protein: new insights for the development of novel anti-HIV-1 drugs.
AID21330Solubility at pH 6.51998Bioorganic & medicinal chemistry letters, Apr-21, Volume: 8, Issue:8
Studies on an immunosuppressive macrolactam, ascomycin: synthesis of a C-33 hydroxyl derivative.
AID69106Inhibitory binding activity against human Immunophilin-FK-506 binding protein 121998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
32-Ascomycinyloxyacetic acid derived immunosuppressants. Independence of immunophilin binding and immunosuppressive potency.
AID18971Distribution coefficient (Log D) value at pH 6.51998Bioorganic & medicinal chemistry letters, Apr-21, Volume: 8, Issue:8
Studies on an immunosuppressive macrolactam, ascomycin: synthesis of a C-33 hydroxyl derivative.
AID1576827Synergistic antifungal activity against Cryptococcus neoformans H99 assessed as FIC index in presence of fluconazole after 48 hrs by checker board assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Biosynthesis of Nonimmunosuppressive FK506 Analogues with Antifungal Activity.
AID142477In vitro immunosuppressive activity in murine splenic T cells1999Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14
C32-O-phenalkyl ether derivatives of the immunosuppressant ascomycin: a tether length study.
AID69103Effective concentration determined was towards FK506 binding protein 12 by competitive binding assay using [3H]-dihydro FK-506 as radioligand1999Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14
C32-O-phenalkyl ether derivatives of the immunosuppressant ascomycin: a tether length study.
AID69113Inhibitory selectivity for human FK506 binding protein 12 and human mixed lymphocyte response(MLR)1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
32-Ascomycinyloxyacetic acid derived immunosuppressants. Independence of immunophilin binding and immunosuppressive potency.
AID21331Solubility at pH 7.41998Bioorganic & medicinal chemistry letters, Apr-21, Volume: 8, Issue:8
Studies on an immunosuppressive macrolactam, ascomycin: synthesis of a C-33 hydroxyl derivative.
AID90649Inhibition of human mixed lymphocyte response (MLR)1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
32-Ascomycinyloxyacetic acid derived immunosuppressants. Independence of immunophilin binding and immunosuppressive potency.
AID69114Immunosuppressive activity in FK506 binding protein 12 binding assay as inhibitory concentration (rIC50) relative to FK506 IC50 (1.2 nM)1999Bioorganic & medicinal chemistry letters, Jan-18, Volume: 9, Issue:2
Preparation and immunosuppressive activity of 32-(O)-acylated and 32-(O)-thioacylated analogues of ascomycin.
AID180555The compound was tested in vivo for lympho-proliferation,against popliteal lymph node(inbred male rats) after i.p. administration1999Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21
Retention of immunosuppressant activity in an ascomycin analogue lacking a hydrogen-bonding interaction with FKBP12.
AID69107The compound was tested for binding affinity against human FK506 binding protein 121999Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21
Retention of immunosuppressant activity in an ascomycin analogue lacking a hydrogen-bonding interaction with FKBP12.
AID221806Compound was tested in vitro for inhibitory activity against human FKBP1998Bioorganic & medicinal chemistry letters, Apr-21, Volume: 8, Issue:8
Studies on an immunosuppressive macrolactam, ascomycin: synthesis of a C-33 hydroxyl derivative.
AID210433Immunosuppressive activity examined in an in vitro model of allogenic T-lymphocyte activation (by MLR assay)1999Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21
Retention of immunosuppressant activity in an ascomycin analogue lacking a hydrogen-bonding interaction with FKBP12.
AID91890In vitro immunosuppressive activity measured in the interleukin-2 receptor gene assay (IL-2 RGA) in mitogen-stimulated human T-cell line; relative to FK5061999Bioorganic & medicinal chemistry letters, Jan-18, Volume: 9, Issue:2
Preparation and immunosuppressive activity of 32-(O)-acylated and 32-(O)-thioacylated analogues of ascomycin.
AID178234Inhibition of rat popliteal lymph node (PLN) hyperplasia when given ip1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
32-Ascomycinyloxyacetic acid derived immunosuppressants. Independence of immunophilin binding and immunosuppressive potency.
AID209941Immunosuppressive activity was determined as the ability to inhibit T cell proliferation.1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
C32-O-imidazol-2-yl-methyl ether derivatives of the immunosuppressant ascomycin with improved therapeutic potential.
AID69120Binding affinity for FK506 binding protein 12 using [3H]-dihydro FK-506 radioligand was determined1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
C32-O-imidazol-2-yl-methyl ether derivatives of the immunosuppressant ascomycin with improved therapeutic potential.
AID18972Distribution coefficent (Log D) value at pH 7.41998Bioorganic & medicinal chemistry letters, Apr-21, Volume: 8, Issue:8
Studies on an immunosuppressive macrolactam, ascomycin: synthesis of a C-33 hydroxyl derivative.
AID140246In vitro immunosuppressive activity measured in the mouse mixed lymphocyte reaction (MLR) expressed as relative inhibitory concentration (rIC50) relative to FK506 IC50 (0.3 nM)1999Bioorganic & medicinal chemistry letters, Jan-18, Volume: 9, Issue:2
Preparation and immunosuppressive activity of 32-(O)-acylated and 32-(O)-thioacylated analogues of ascomycin.
AID176172Compound was tested in vivo for immunosuppressive activity using rat popliteal lymph node (rPLN) hyperplasia assay1998Bioorganic & medicinal chemistry letters, Apr-21, Volume: 8, Issue:8
Studies on an immunosuppressive macrolactam, ascomycin: synthesis of a C-33 hydroxyl derivative.
AID90650Compound was tested in vitro for inhibition of human mixed lymphocyte proliferation (HuMLR)1998Bioorganic & medicinal chemistry letters, Apr-21, Volume: 8, Issue:8
Studies on an immunosuppressive macrolactam, ascomycin: synthesis of a C-33 hydroxyl derivative.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (162)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (1.85)18.7374
1990's77 (47.53)18.2507
2000's52 (32.10)29.6817
2010's26 (16.05)24.3611
2020's4 (2.47)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.09 (24.57)
Research Supply Index5.12 (2.92)
Research Growth Index6.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.61%)5.53%
Reviews12 (7.27%)6.00%
Case Studies1 (0.61%)4.05%
Observational0 (0.00%)0.25%
Other151 (91.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]